ArticleFrontiers in medicine2025
Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rewiring Atopic Dermatitis: Alarmin Cytokines at the Core of Barrier-Immune-Neuro-Microbiome Networks.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the percentage of eosinophils (EOS) in peripheral blood and disease activity and severity in bullous pemphigoid (BP) patients. Methods: Blood samples from 61 BP inpatients were collected on the first day of admission and again 1 week after systemic corticosteroid treatment. Additionally, blood specimens were collected from 61 healthy controls. The concentrations of IL-17, IL-18, IL-22, IL-25, IgE, and anti-BP180 or anti-BP230 antibodies were measured using ELISA kits. Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman's correlation analysis. Results: The mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all Conclusion: IL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as biological indicators for monitoring disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.